skin

anti-PD-1 monoclonal antibody

Thesis

[KNOWN] Use established PD-1 blockade as the conservative benchmark for advanced melanoma and selected advanced cutaneous squamous cell carcinoma. [INFERRED] The next testable increment is identifying biomarker-defined nonresponders rather than treating broad skin cancer as one disease.

Mechanism

[KNOWN] Pembrolizumab blocks PD-1 signaling and can restore antitumor T-cell activity. [INFERRED] Response heterogeneity may reflect tumor antigen presentation, T-cell exclusion, or an immunosuppressive microenvironment.

Kill experiment

In a prospectively defined melanoma or cutaneous squamous cell carcinoma cohort, demonstrate that PD-L1 status, antigen-presentation markers, T-cell exclusion, and immune-suppressive features do not predict response or resistance beyond clinical covariates, or show no activity in the specified treatment-naive indication.

Why it died

This is an established PD-1 therapy for selected melanoma and cutaneous squamous cell carcinoma, not an unreviewed hypothesis. The pack contains no Open Targets result, known-drug record, trial record, or evidence supporting extrapolation to undifferentiated "skin" disease. Its proposed biomarker increment is generic inference, not a defined testable target.

anti-PD-1 plus anti-LAG-3 monoclonal antibodies

Thesis

[KNOWN] This is an established immunotherapy option in advanced melanoma. [INFERRED] It is a rational comparator for tumors with inadequate response or rapid progression on PD-1 pathway therapy, but the benefit-risk tradeoff should be tested by subtype and prior exposure.

Mechanism

[KNOWN] Nivolumab inhibits PD-1, while relatlimab inhibits LAG-3. [INFERRED] Dual checkpoint blockade may improve T-cell function where both inhibitory pathways are active.

Kill experiment

In a biomarker-selected melanoma study enriched for concurrent PD-1 and LAG-3 activity, show that adding relatlimab produces no clinically meaningful improvement over nivolumab alone in response durability or survival, with acceptable assay quality and exposure.

Why it died

This is an established combination for advanced melanoma, not an unreviewed hypothesis for skin disease. The pack provides no trial or target evidence for use outside that histology. The claim that dual PD-1/LAG-3 blockade benefits PD-1-refractory tumors is an inference without a defined population, endpoint, or causal evidence, and the candidate offers no basis for treating generic skin disease.

BRAF inhibitor plus MEK inhibitor

Thesis

[KNOWN] This combination is a standard targeted option for advanced melanoma harboring an activating BRAF V600 alteration. [INFERRED] It is a strong molecularly selected branch, not a general treatment for unselected skin cancer.

Mechanism

[KNOWN] Dabrafenib inhibits mutant BRAF and trametinib inhibits MEK1/2 downstream in the MAPK pathway. [INFERRED] Combined pathway suppression can reduce adaptive MAPK reactivation compared with single-agent BRAF inhibition.

Kill experiment

In independently confirmed BRAF V600-positive advanced melanoma, demonstrate in a controlled comparison that the combination does not improve progression control or duration of response over an appropriate targeted comparator, or test a non-BRAF-V600 population and show no genotype-specific activity.

Why it died

This is a standard targeted regimen for BRAF V600-mutant advanced melanoma, not an unreviewed hypothesis. Its relevance is limited to a molecularly defined melanoma subgroup and is unsupported for undifferentiated skin disease; the pack has no target or trial evidence. The adaptive-MAPK-resistance rationale is stated as inference and does not establish a new candidate.

anti-PD-1 monoclonal antibody

Thesis

[KNOWN] Cemiplimab is an established systemic treatment for advanced cutaneous squamous cell carcinoma when local therapy is unsuitable or insufficient. [INFERRED] It provides a histology-specific benchmark distinct from melanoma immunotherapy datasets.

Mechanism

[KNOWN] Cemiplimab blocks PD-1 signaling to enhance antitumor T-cell responses. [INFERRED] Lack of response may be investigated through tumor antigen presentation and immune-cell exclusion measurements.

Kill experiment

In advanced cutaneous squamous cell carcinoma meeting the stated systemic-treatment criteria, show prospectively that cemiplimab has no reproducible objective response or durable disease control, or that proposed antigen-presentation and immune-exclusion features fail to distinguish responders from nonresponders.

Why it died

Cemiplimab is an established systemic treatment for advanced cutaneous squamous cell carcinoma, not an unreviewed hypothesis. It cannot represent a general skin-disease solution, and the pack contains no supporting Open Targets, drug, trial, or disease-specific evidence. The proposed antigen-presentation and immune-exclusion explanation for nonresponse is generic inference rather than a validated hypothesis.

Hedgehog-pathway inhibitor

Thesis

[KNOWN] Vismodegib is an established option for advanced or locally advanced basal cell carcinoma in appropriate settings. [INFERRED] It is a plausible conservative candidate only for Hedgehog-dependent basal cell carcinoma, not for melanoma or cutaneous squamous cell carcinoma.

Mechanism

[KNOWN] Vismodegib inhibits Smoothened, suppressing aberrant Hedgehog pathway signaling driven commonly by PTCH1 or SMO alterations in basal cell carcinoma. [INFERRED] Resistance could arise through downstream pathway reactivation.

Kill experiment

In molecularly confirmed Hedgehog-pathway-dependent advanced basal cell carcinoma, show no meaningful response or progression control at clinically tolerated exposure, or show that PTCH1/SMO pathway activation does not enrich for benefit compared with pathway-negative tumors.

Why it died

Vismodegib is an established Hedgehog inhibitor for appropriately selected advanced or locally advanced basal cell carcinoma, not an unreviewed candidate. Its mechanism and disease restriction are already known, while the pack supplies no Open Targets, drug, trial, or new evidence. It is irrelevant to melanoma, cutaneous squamous cell carcinoma, and undifferentiated "skin" disease; resistance by downstream reactivation is only an inference.

autologous tumor-infiltrating lymphocyte therapy

Thesis

[KNOWN] Lifileucel is an established cellular therapy option for selected advanced melanoma after prior systemic treatment. [INFERRED] A testable increment is determining whether pretreatment features of T-cell infiltration or tumor antigenicity predict durable benefit.

Mechanism

[KNOWN] Lifileucel expands and reinfuses autologous tumor-infiltrating lymphocytes. [INFERRED] Its activity depends on recovering tumor-reactive T-cell populations capable of recognizing patient-specific tumor antigens.

Kill experiment

In consecutively treated eligible melanoma patients, prospectively measure baseline T-cell infiltration and tumor antigenicity and show that these features do not predict product generation, objective response, or durable benefit, or demonstrate that manufacturing failure or post-infusion persistence makes the proposed biomarker-selected strategy clinically infeasible.

Why it died

Lifileucel is an established autologous TIL therapy for selected previously treated advanced melanoma, not an unreviewed hypothesis. The pack contains no trial or target evidence and does not justify extending it to generic skin disease. The proposed predictors, T-cell infiltration and tumor antigenicity, are broad inferred correlates without a specified assay or validated causal link.

gp100-directed ImmTAC T-cell engager

Thesis

[KNOWN] Tebentafusp has clinical activity in HLA-A*02:01-positive uveal melanoma. [INFERRED] It is a wrong-but-plausible decoy for a broad skin-cancer query because melanoma biology is often conflated across cutaneous and uveal disease; it should not be generalized to cutaneous melanoma without evidence.

Mechanism

[KNOWN] Tebentafusp redirects T cells toward gp100-expressing cells through an engineered T-cell receptor domain and anti-CD3 domain. [INFERRED] Applicability depends on HLA-A*02:01 and sufficient gp100 presentation.

Why it died

The agent is real, but the pack identifies its validated disease as HLA-A*02:01-positive uveal melanoma [KNOWN]. Uveal melanoma is ocular rather than cutaneous skin cancer, and the pack explicitly labels generalization to cutaneous melanoma as unsupported [INFERRED]. This fails the disease-target triage for a skin-cancer query.

anti-CTLA-4 monoclonal antibody

Thesis

[KNOWN] Ipilimumab is an established melanoma immunotherapy and has been used in combination or later-line settings. [INFERRED] As a standalone broad skin-cancer proposal it is a wrong-but-plausible decoy, useful for testing whether the critic rejects nonspecific extrapolation from melanoma.

Mechanism

[KNOWN] Ipilimumab blocks CTLA-4-mediated inhibitory signaling during T-cell priming. [INFERRED] Increased T-cell activation may improve tumor immune recognition but can also increase immune-mediated toxicity.

Kill experiment

A defined cutaneous melanoma comparison showing no clinically meaningful activity or no usable role relative to modern checkpoint regimens would falsify the proposed benchmark, while lack of evidence in other skin histologies already falsifies broad extrapolation.

Why it died

The candidate's own thesis identifies standalone broad skin-cancer use as a wrong-but-plausible decoy. CTLA-4 blockade supplies only a generic T-cell-priming step; the pack provides no disease-specific mutation, target dependency, histology, or causal path from that step to symptoms for the unresolved skin query. Its melanoma history cannot be extrapolated to unspecified skin disease, and there are no query-specific targets, trials, or evidence entries supporting that extrapolation.